Overview
Diptiman Choudhury practices practicing medicine in Patiala, India.
Their clinical expertise encompasses Lung Adenocarcinoma, Inflammatory Breast Cancer, and Stomach Cancer.
They are actively involved in clinical research, co-authoring 62 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Diptiman Choudhury
Is Diptiman Choudhury a top-rated expert for Lung Adenocarcinoma?
MediFind is an objective health platform that identifies experts based on real-world data. Diptiman Choudhury is classified as an Experienced expert for Lung Adenocarcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Diptiman Choudhury participate in research or clinical trials?
Yes. Diptiman Choudhury has published 62 articles and abstracts on conditions like Lung Adenocarcinoma. You can view a list of Diptiman Choudhury's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Inflammatory Breast CancerChoudhury isExperienced. Learn about Inflammatory Breast Cancer.
- Lung AdenocarcinomaChoudhury isExperienced. Learn about Lung Adenocarcinoma.
- Stomach CancerChoudhury isExperienced. Learn about Stomach Cancer.